The mechanisms for sensitization of HR-defective cancers to PARPi vs. Polθi are, thus, at least partly distinct, which is consistent with the additive cytotoxicity of these two inhibitors observed in HR defective cells13,15,16. The gene discussed is ENSG00000223804; the disease is cancer.